当前位置： SCI文献检索 > GYNECOLOGIC ONCOLOGY期刊下所有文献 > Therapeutic targeting of the TNF superfamily: a promising treatment for advanced endometrial adenocarcinoma.

Therapeutic targeting of the TNF superfamily: a promising treatment for advanced endometrial adenocarcinoma.

Abstract：

:Surgical treatment including total abdominal hysterectomy+bilateral salpingo oopherectomy (TAH+BSO) with pelvic and para-aortic lymphadenectomy may not be sufficient to treat cases with advanced endometrial adenocarcinoma (EAC), and in these cases, adjuvant treatments including radiotherapy and/or chemotherapy, are employed based upon the tumor location, type and stage of the disease. These treatment modalities have high incidence of systemic toxicity, thereby compelling clinicians to look for targeted therapy aiming specifically at the malignant cells. Bevacizumab (anti-VEGF), temsirolimus (mTOR inhibitor) and aflibercept (VEGF trap) are already under clinical trials in women with EAC. Targeting the ligands and receptors of the tumor necrosis factor (TNF) superfamily holds promise in this regard. The objective of this review is to provide an overview of the various mechanisms and pathways related to the TNF superfamily involved in advanced EAC and to identify the new therapeutic strategies for specifically targeting these impaired pathways. In addition, the development of treatments for EAC is also discussed. The possible therapeutic treatments include targeting TNFα and its receptors using monoclonal antibodies (MAbs) such as infliximab, adalimumab, etanercept, and certolizumab. Proteosome inhibitors including bortezomib and the anti CD-20 agent rituximab are used to inhibit the NF-κB pathway. Other options include targeting the FAS (CD95) pathway and the TNF-related apoptosis-inducing ligand (TRAIL) pathway using agents such as mapatumab, lexatumumab, and conatumumab. These pathways are known to be involved in the pathogenesis of EAC. Moreover, there is adequate evidence to warrant the use of drugs that target the TNF superfamily for the treatment of advanced EAC.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Thangaraju S,Subramani E,Chakravarty B,Chaudhury K

doi

10.1016/j.ygyno.2012.07.125

subject

Has Abstract

pub_date

2012-11-01 00:00:00

pages

426-32

issue

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(12)00651-8

journal_volume

127

pub_type

杂志文章,评审

在线工具

Therapeutic targeting of the TNF superfamily: a promising treatment for advanced endometrial adenocarcinoma.